| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5023269 | LILLY | 3-aryloxy-3-substituted propanamines |
Jun, 2013
(10 years ago) | |
|
US5023269 (Pediatric) | LILLY | 3-aryloxy-3-substituted propanamines |
Dec, 2013
(10 years ago) | |
| US5508276 | LILLY | Duloxetine enteric pellets |
Jul, 2014
(9 years ago) | |
|
US5508276 (Pediatric) | LILLY | Duloxetine enteric pellets |
Jan, 2015
(9 years ago) | |
| US6596756 | LILLY | Treatment of fibromyalgia |
Sep, 2019
(4 years ago) | |
|
US6596756 (Pediatric) | LILLY | Treatment of fibromyalgia |
Mar, 2020
(4 years ago) | |
Cymbalta is owned by Lilly.
Cymbalta contains Duloxetine Hydrochloride.
Cymbalta has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Cymbalta are:
- US5023269
- US5023269*PED
- US5508276
- US5508276*PED
- US6596756
- US6596756*PED
Cymbalta was authorised for market use on 03 August, 2004.
Cymbalta is available in capsule, delayed rel pellets;oral dosage forms.
Cymbalta can be used as management of fibromyalgia (fm), method of treating anxiety.
The generics of Cymbalta are possible to be released after 20 April, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 20, 2023 |
| M(M-61) | Oct 18, 2015 |
| New Indication(I-632) | Nov 04, 2013 |
| Pediatric Exclusivity(PED) | May 04, 2014 |
| New Indication(I-617) | Nov 19, 2012 |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 August, 2004
Treatment: Method of treating anxiety; Management of fibromyalgia (fm)
Dosage: CAPSULE, DELAYED REL PELLETS;ORAL
CYMBALTA family patents
